Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C.
Fontana
R J
RJ
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA.
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D007669:Kidney Calculi / Q000139:chemically induced* / Q000737:chemistry; D008297:Male; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D014527:Uric Acid
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014527:Uric Acid; D012254:Ribavirin